Evaluation of the symptomatic treatment of residual neurological symptoms in Wilson disease

European Neurology

Volumn 64, Issue 2, 2010, Pages 83-87

  Hölscher, Sara ^a   Leinweber, Barbara ^a   Hefter, Harald ^b   Reuner, Ulrike ^c   Günther, Peter ^d   Weiss, Karl Heinz ^e   Oertel, Wolfgang H ^a   Möller, Jens Carsten ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Movement disorder; Symptomatic treatment; Wilson disease

Indexed keywords

AMANTADINE; BACLOFEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIPERIDEN; BOTULINUM TOXIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; LEVODOPA; METIXENE; PENICILLAMINE; PRIMIDONE; PROPRANOLOL; ROPINIROLE; TETRABENAZINE; TIAPRIDE; TRIENTINE; TRIHEXYPHENIDYL; ZINC;

ADULT; ARTICLE; DYSTONIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PARKINSONISM; PRIORITY JOURNAL; QUESTIONNAIRE; SYMPTOMATOLOGY; TREMOR; WILSON DISEASE;

ADULT; AGED; ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; CHOLINERGIC ANTAGONISTS; FEMALE; HEALTH SURVEYS; HEPATOLENTICULAR DEGENERATION; HUMANS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; QUESTIONNAIRES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954192986     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000316066     Document Type: Article

References (9)

1. Ferenci P: Pathophysiology and clinical features of Wilson disease. Met Brain Dis 2004; 19: 229-239.
2. Roberts EA, Schilsky ML: A practice guideline on Wilson disease. Hepatology 2003; 37: 1475-1492.
3. Ferenci P, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I, Schilsky M, Cox D, Berr F: Diagnosis and phenotypic classification of Wilson disease. Liver Int 2003; 23: 139-142.
4. Brewer GJ: Recognition, diagnosis, and management of Wilson's disease. Proc Soc Exp Biol Med 2000; 223: 39-46.
5. Brewer GJ: Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment. CNS Drugs 2005; 19: 185-192.
6. Czlonkowska A, Tarnacka B, Litwin T, Gajda J, Rodo M: Wilson's disease - cause of mortality in 164 patients during 1992-2003 observation period. J Neurol 2005; 252: 698-703.
7. Leinweber B, Möller JC, Scherag A, Reuner U, Günther P, Lang CJG, Schmidt HHJ, Schrader C, Bandmann O, Czlonkowska A, Oertel WH, Hefter H: Evaluation of the Unified Wilson's Disease Rating Scale (UWDRS) in German patients with treated Wilson's disease. Mov Disord 2008; 23: 54-62.
8. Svetel M, Potrebic A, Pekmezovic T, Tomic A, Kresojevic N, Jesic R, Dragasevic N, Kostic VS: Neuropsychiatric aspects of treated Wilson's disease. Parkinsonism Relat Disord 2009; 15: 772-775.
9. Barthel M, Hermann W, Kluge R, Hesse S, Collingridge DR, Wagner A, Sabri O: Concordant pre- and postsynaptic deficits of dopaminergic neurotransmission in neurologic Wilson disease. AJNR Am J Neuroradiol 2003; 24: 234-238.